Cited by CrossRef (86)
- Rémi Moirand, Filipe Galvao, Clément Dondé. Pramipexole and Selegiline Combination Therapy in a Case of Treatment-Resistant Depression. J Clin Psychopharmacol 2019;39:684

- Bijo Mathew, Della G. T. Parambi, Githa E. Mathew, Md. Sahab Uddin, Sini T. Inasu, Hoon Kim, Akash Marathakam, Mazhuvancherry Kesavan Unnikrishnan, Simone Carradori. Emerging therapeutic potentials of dual‐acting MAO and AChE inhibitors in Alzheimer's and Parkinson's diseases. Archiv der Pharmazie 2019;352

- Lieven D. Declercq, Rik Vandenberghe, Koen Van Laere, Alfons Verbruggen, Guy Bormans. Drug Development in Alzheimer’s Disease: The Contribution of PET and SPECT. Front. Pharmacol. 2016;7

- D. P. Devanand, R. Fremont. Tasman’s Psychiatry. 2016.

- Fabio Rizzo-Aguiar, Carlos A.D. Sousa, Xerardo Garcia-Mera, José E. Rodríguez-Borges. Synthesis and characterization of 1-pyrindane derivatives as rasagiline analogues. Chemical Data Collections 2016;5-6:21

- Jing Xu, Feifei Ji, Xiaocong Sun, Xiangrong Cao, Shen Li, Yasushi Ohizumi, Yuanqiang Guo. Characterization and Biological Evaluation of Diterpenoids from Casearia graveolens. J. Nat. Prod. 2015;78:2648

- Gerard Esteban, Jennifer Allan, Abdelouahid Samadi, Andrea Mattevi, Mercedes Unzeta, José Marco-Contelles, Claudia Binda, Rona R. Ramsay. Kinetic and structural analysis of the irreversible inhibition of human monoamine oxidases by ASS234, a multi-target compound designed for use in Alzheimer's disease. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 2014;1844:1104

- Yanier Nuñez-Figueredo, Jeney Ramírez-Sánchez, Gisele Hansel, Elisa Nicoloso Simões Pires, Nelson Merino, Odalys Valdes, René Delgado-Hernández, Alicia Lagarto Parra, Estael Ochoa-Rodríguez, Yamila Verdecia-Reyes, Christianne Salbego, Silvia L. Costa, Diogo O. Souza, Gilberto L. Pardo-Andreu. A novel multi-target ligand (JM-20) protects mitochondrial integrity, inhibits brain excitatory amino acid release and reduces cerebral ischemia injury in vitro and in vivo. Neuropharmacology 2014;85:517

- John P.M. Finberg. Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: Focus on modulation of CNS monoamine neurotransmitter release. Pharmacology & Therapeutics 2014;143:133

- Wei Liu, Ming Lang, Moussa B.H. Youdim, Tamar Amit, Yewei Sun, Zaijun Zhang, Yuqiang Wang, Orly Weinreb. Design, synthesis and evaluation of novel dual monoamine-cholinesterase inhibitors as potential treatment for Alzheimer’s disease. Neuropharmacology 2016;109:376

- Avinash C. Tripathi, Savita Upadhyay, Sarvesh Paliwal, Shailendra K. Saraf. Privileged scaffolds as MAO inhibitors: Retrospect and prospects. European Journal of Medicinal Chemistry 2018;145:445

- Naif H. Ali, Hayder M. Al‐Kuraishy, Ali I. Al‐Gareeb, Athanasios Alexiou, Marios Papadakis, Ali Abdullah AlAseeri, Mubarak Alruwaili, Hebatallah M. Saad, Gaber El‐Saber Batiha. BDNF/TrkB activators in Parkinson's disease: A new therapeutic strategy. J Cellular Molecular Medi 2024;28

- Zheng Liu, Wei Cai, Ming Lang, Ruizuo Yan, Zhenshen Li, Gaoxiao Zhang, Pei Yu, Yuqiang Wang, Yewei Sun, Zaijun Zhang. Neuroprotective Effects and Mechanisms of Action of Multifunctional Agents Targeting Free Radicals, Monoamine Oxidase B and Cholinesterase in Parkinson’s Disease Model. J Mol Neurosci 2017;61:498

- Young-Cheol Lim, Hyeongi Kim, Sang Moo Lim, Jin Su Kim. Genetic analysis of a novel antioxidant multi-target iron chelator, M30 protecting against chemotherapy-induced alopecia in mice. BMC Cancer 2019;19

- Pankaj Mishra, Amit Kumar, Gautam Panda. Anti-cholinesterase hybrids as multi-target-directed ligands against Alzheimer’s disease (1998–2018). Bioorganic & Medicinal Chemistry 2019;27:895

- Rona R. Ramsay. Molecular aspects of monoamine oxidase B. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2016;69:81

- Aitor Carneiro, Eugenio Uriarte, Fernanda Borges, Maria João Matos. Propargylamine: an Important Moiety in Drug Discovery. Future Med. Chem. 2023;15:211

- Ali Ulvi Uca, Hasan Hüseyin Kozak. A case of rasagiline-induced spontaneous orgasms in a female patient. Parkinsonism & Related Disorders 2014;20:929

- Sonali S. Bharate, Serge Mignani, Ram A. Vishwakarma. Why Are the Majority of Active Compounds in the CNS Domain Natural Products? A Critical Analysis. J. Med. Chem. 2018;61:10345

- Maria L Bolognesi, Michele Rossi. Encyclopedia of Life Sciences. 2018.

- Nikolay T. Tzvetkov, Sonja Hinz, Petra Küppers, Marcus Gastreich, Christa E. Müller. Indazole- and Indole-5-carboxamides: Selective and Reversible Monoamine Oxidase B Inhibitors with Subnanomolar Potency. J. Med. Chem. 2014;57:6679

- Md. Sahab Uddin, Md. Tanvir Kabir, Md. Habibur Rahman, Md. Abdul Alim, Md. Motiar Rahman, Anurag Khatkar, Abdullah Al Mamun, Abdur Rauf, Bijo Mathew, Ghulam Md. Ashraf. Exploring the Multifunctional Neuroprotective Promise of Rasagiline Derivatives for Multi-Dysfunctional Alzheimer’s Disease. CPD 2020;26:4690

- Sarah Chajkowski-Scarry, John M Rimoldi. Monoamine Oxidase a and B Substrates: Probing the Pathway for Drug Development. Future Med. Chem. 2014;6:697

- Ramón Cacabelos, Pablo Cacabelos, Clara Torrellas, Iván Tellado, Juan C. Carril. Pharmacogenomics in Drug Discovery and Development. 2014.

- İsmail Okan Ateş, Asaf Evrim Evren, Begüm Nurpelin Sağlik, Leyla Yurttaş. New indane derivatives containing 2-hydrazinothiazole as potential acetylcholinesterase and monoamine oxidase-B inhibitors. 2021;76:417

- N. André Sasaki, Pascal Sonnet. A Novel Multi-Target Strategy to Attenuate the Progression of Parkinson's Disease by Diamine Hybrid AGE/ALE Inhibitor. Future Med. Chem. 2021;13:2185

- Elahe Zarini-Gakiye, Javad Amini, Nima Sanadgol, Gholamhassan Vaezi, Kazem Parivar. Recent Updates in the Alzheimer’s Disease Etiopathology and Possible Treatment Approaches: A Narrative Review of Current Clinical Trials. CMP 2020;13:273

- Rona R. Ramsay, Magdalena Majekova, Milagros Medina, Massimo Valoti. Key Targets for Multi-Target Ligands Designed to Combat Neurodegeneration. Front. Neurosci. 2016;10

- Sudhir Raghavan, David S. Baskin, Martyn A. Sharpe. Encyclopedia of Biological Chemistry III. 2016.

- María Eugenia Prados, Carmen Navarrete, Adela García-Martín, Isabel Lastres-Cubillo, Francisco Ponce-Díaz, José Martínez-Orgado, Eduardo Muñoz. VCE-005.1, an hypoxia mimetic betulinic acid derivative, induces angiogenesis and shows efficacy in a murine model of traumatic brain injury. Biomedicine & Pharmacotherapy 2023;162:114715

- Awwad A. Radwan, Fars K. Alanazi, Mohammad Raish, Joazaizulfazli Jamalis. Design and synthesis of multi-functional small-molecule based inhibitors of amyloid-β aggregation: Molecular modeling and in vitro evaluation. PLoS ONE 2023;18:e0286195

- Yash Pal Singh, Amruta Pandey, Swati Vishwakarma, Gyan Modi. A review on iron chelators as potential therapeutic agents for the treatment of Alzheimer’s and Parkinson’s diseases. Mol Divers 2019;23:509

- Paolo Guglielmi, Simone Carradori, Ilaria D’Agostino, Cristina Campestre, Jacobus P. Petzer. An updated patent review on monoamine oxidase (MAO) inhibitors. Expert Opinion on Therapeutic Patents 2022;32:849

- Ganesh N. Pandian, Rhys D. Taylor, Syed Junetha, Abhijit Saha, Chandran Anandhakumar, Thangavel Vaijayanthi, Hiroshi Sugiyama. Alteration of epigenetic program to recover memory and alleviate neurodegeneration: prospects of multi-target molecules. Biomater. Sci. 2014;2:1043

- Paolo Guglielmi, Simone Carradori, Alessandra Ammazzalorso, Daniela Secci. Novel approaches to the discovery of selective human monoamine oxidase-B inhibitors: is there room for improvement?. Expert Opinion on Drug Discovery 2019;14:995

- Bilqees Sameem, Mina Saeedi, Mohammad Mahdavi, Abbas Shafiee. A review on tacrine-based scaffolds as multi-target drugs (MTDLs) for Alzheimer's disease. European Journal of Medicinal Chemistry 2017;128:332

- David S. Goldstein, Irwin J. Kopin, Yehonatan Sharabi. Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders. Pharmacology & Therapeutics 2014;144:268

- Cristian Follmer. Monoamine oxidase and α-synuclein as targets in Parkinson’s disease therapy. Expert Review of Neurotherapeutics 2014;14:703

- Salvatore Bongarzone, Matteo Staderini, Maria Laura Bolognesi. Multitarget Ligands and Theranostics: Sharpening the Medicinal Chemistry Sword Against Prion Diseases. Future Med. Chem. 2014;6:1017

- Hugo Juárez Olguín, David Calderón Guzmán, Ernestina Hernández García, Gerardo Barragán Mejía, Anne-Laure Bulteau. The Role of Dopamine and Its Dysfunction as a Consequence of Oxidative Stress. Oxidative Medicine and Cellular Longevity 2016;2016

- Veda Prachayasittikul, Ratchanok Pingaew, Supaluk Prachayasittikul, Virapong Prachayasittikul. 8-Hydroxyquinolines: A Promising Pharmacophore Potentially Developed as Disease-Modifying Agents for Neurodegenerative Diseases: A Review. HETEROCYCLES 2022;105:202

- Maria Laura Bolognesi, Andrea Cavalli. Multitarget Drug Discovery and Polypharmacology. ChemMedChem 2016;11:1190

- S. O. Bachurin. A review of drugs for treatment of Alzheimer’s disease in clinical trials: main trends. Z. nevrol. psikhiatr. im. S.S. Korsakova 2016;116:77

- Jing Xu, Jing Kang, Xiaocong Sun, Xiangrong Cao, Kasimu Rena, Dongho Lee, Quanhui Ren, Shen Li, Yasushi Ohizumi, Yuanqiang Guo. Di- and Triterpenoids from the Leaves of Casearia balansae and Neurite Outgrowth Promoting Effects of PC12 Cells. J. Nat. Prod. 2016;79:170

- Banibrata Das, Ashoka Kandegedara, Liping Xu, Tamara Antonio, Timothy Stemmler, Maarten E. A. Reith, Aloke K. Dutta. A Novel Iron(II) Preferring Dopamine Agonist Chelator as Potential Symptomatic and Neuroprotective Therapeutic Agent for Parkinson’s Disease. ACS Chem. Neurosci. 2017;8:723

- Anastasios Fotinos, Yongjin Zhu, Lilly L. J. Mao, Nazem Atassi, Edward W. Zhou, Sarfraz Ahmad, Yingjun Guan, James D. Berry, Merit E. Cudkowicz, Xin Wang. Melatonin, Neuroprotective Agents and Antidepressant Therapy. 2017.

- Payel Bhattacharjee, Jyotirmoy Mitra, Debasish Bhattacharyya. Toxins and Drug Discovery. 2017.

- Pablo Duarte, Antonio Cuadrado, Rafael León. Reactive Oxygen Species. 2017.

- JessicaD Panes, Aline Wendt, Oscar Ramirez-Molina, PatricioA Castro, Jorge Fuentealba. Deciphering the role of PGC-1α in neurological disorders: from mitochondrial dysfunction to synaptic failure. Neural Regen Res 2022;17:237

- Niraj Kumar Jha, Saurabh Kumar Jha, Renu Sharma, Dhiraj Kumar, Rashmi K. Ambasta, Pravir Kumar. Hypoxia-Induced Signaling Activation in Neurodegenerative Diseases: Targets for New Therapeutic Strategies. Journal of Alzheimer’s Disease 2018;62:15

- Mrudang Shah, Subramanian Rajagopalan, Liping Xu, Chandrashekhar Voshavar, Yevgeniya Shurubor, Flint Beal, Julie K. Andersen, Aloke K. Dutta. The high‐affinity D2/D3 agonist D512 protects PC12 cells from 6‐OHDA‐induced apoptotic cell death and rescues dopaminergic neurons in the MPTP mouse model of Parkinson's disease. Journal of Neurochemistry 2014;131:74

- Andrew Holt, Dmitriy Matveychuk, Darrell D. Mousseau, Glen B. Baker. Encyclopedia of Psychopharmacology. 2014.

- Amirhossein Maghsoudi, Saideh Fakharzadeh, Maryam Hafizi, Maryam Abbasi, Fatemeh Kohram, Shima Sardab, Abbas Tahzibi, Somayeh Kalanaky, Mohammad Hassan Nazaran. Neuroprotective effects of three different sizes nanochelating based nano complexes in MPP(+) induced neurotoxicity. Apoptosis 2015;20:298

- Rebecca E. Hughes, Katarina Nikolic, Rona R. Ramsay. One for All? Hitting Multiple Alzheimer's Disease Targets with One Drug. Front. Neurosci. 2016;10

- Satoka Kasai, Toru Yoshihara, Olga Lopatina, Katsuhiko Ishihara, Haruhiro Higashida. Selegiline Ameliorates Depression-Like Behavior in Mice Lacking the CD157/BST1 Gene, a Risk Factor for Parkinson’s Disease. Front. Behav. Neurosci. 2017;11

- Nerea Alonso, Olga Caamaño, Francisco J. Romero-Duran, Feng Luan, M. Natália D. S. Cordeiro, Matilde Yañez, Humberto González-Díaz, Xerardo García-Mera. Model for High-Throughput Screening of Multitarget Drugs in Chemical Neurosciences: Synthesis, Assay, and Theoretic Study of Rasagiline Carbamates. ACS Chem. Neurosci. 2013;4:1393

- Payel Bhattacharjee, Jyotirmoy Mitra, Debasish Bhattacharyya. Toxins and Drug Discovery. 2013.

- Hiroko Munakata, Risa Ishikawa, Toshiaki Saitoh, Toshie Kambe, Terumasa Chiba, Kyoji Taguchi, Kenji Abe. Preventative effects of 1-methyl-1,2,3,4-tetrahydroisoquinoline derivatives (N-functional group loading) on MPTP-induced parkinsonism in mice. Can. J. Physiol. Pharmacol. 2022;100:594

- Akhil Kumar, Ashok Sharma. Computational Modeling of Drugs Against Alzheimer’s Disease. 2022.

- . Parkinson's Disease. 2022.

- Jan Korábečný, Eugenie Nepovimová, Tereza Cikánková, Katarína Špilovská, Lucie Vašková, Eva Mezeiová, Kamil Kuča, Jana Hroudová. Newly Developed Drugs for Alzheimer’s Disease in Relation to Energy Metabolism, Cholinergic and Monoaminergic Neurotransmission. Neuroscience 2018;370:191

- Jiqing Cao, Jianwei Hou, Jing Ping, Dongming Cai. Advances in developing novel therapeutic strategies for Alzheimer’s disease. Mol Neurodegeneration 2018;13

- Shinghung Mak, Wenming Li, Hongjun Fu, Jialie Luo, Wei Cui, Shengquan Hu, Yuanping Pang, Paul R. Carlier, Karl Wahkeung Tsim, Rongbiao Pi, Yifan Han. Promising tacrine/huperzine A‐based dimeric acetylcholinesterase inhibitors for neurodegenerative disorders: From relieving symptoms to modifying diseases through multitarget. Journal of Neurochemistry 2021;158:1381

- Lovedeep Singh, Harpreet Kaur, Girish Chandra Arya, Rajbir Bhatti. Neuroprotective potential of formononetin, a naturally occurring isoflavone phytoestrogen. Chem Biol Drug Des 2024;103

- Anne Robert, Yan Liu, Michel Nguyen, Bernard Meunier. Regulation of Copper and Iron Homeostasis by Metal Chelators: A Possible Chemotherapy for Alzheimer’s Disease. Acc. Chem. Res. 2015;48:1332

- Kristin Part, Kai Künnis-Beres, Helen Poska, Tiit Land, Ruth Shimmo, Sandra Zetterström Fernaeus. Amyloid β25–35 induced ROS-burst through NADPH oxidase is sensitive to iron chelation in microglial Bv2 cells. Brain Research 2015;1629:282

- Maylin Wong-Guerra, Yanay Montano-Peguero, Daniela Hernández-Enseñat, Jeney Ramírez-Sánchez, Abel Mondelo-Rodríguez, Alejandro Saúl Padrón-Yaquis, Enrique García-Alfonso, Luis Arturo Fonseca-Fonseca, Yanier Nuñez-Figueredo. Mitochondrial protective properties exerted by JM-20 in a dementia model induced by intracerebroventricular administration of streptozotocin in mice. Behavioural Brain Research 2025;480:115385

- Damijan Knez, Matej Sova, Urban Košak, Stanislav Gobec. Dual Inhibitors of Cholinesterases and Monoamine Oxidases for Alzheimer’S Disease. Future Med. Chem. 2017;9:811

- D. P. Devanand, R. Fremont. Tasman’s Psychiatry. 2017.

- Cheng-Xin Gong, Fei Liu, Khalid Iqbal, G. Perry, J. Avila, P.I. Moreira, A.A. Sorensen, M. Tabaton. Multifactorial Hypothesis and Multi-Targets for Alzheimer’s Disease. JAD 2018;64:S107

- Sven-Eric Pålhagen. Parkinson's Disease. 2018.

- Chun-Sing Lam, Jing-Jie Li, George Lim Tipoe, Moussa B. H. Youdim, Man-Lung Fung, Muzamil Ahmad. Monoamine oxidase A upregulated by chronic intermittent hypoxia activates indoleamine 2,3-dioxygenase and neurodegeneration. PLoS ONE 2017;12:e0177940

- K. Lutsenko, S. Hagenow, A. Affini, D. Reiner, H. Stark. Rasagiline derivatives combined with histamine H3 receptor properties. Bioorganic & Medicinal Chemistry Letters 2019;29:126612

- Dawid Panek, Tomasz Wichur, Justyna Godyń , Anna Pasieka, Barbara Malawska. Advances Toward Multifunctional Cholinesterase and β-Amyloid Aggregation Inhibitors. Future Med. Chem. 2017;9:1835

- Carlos A. D. Sousa, Ivo E. Sampaio-Dias, Fabio Rizzo-Aguiar, Xerardo Garcia-Mera, José E. Rodríguez-Borges. Enantiopure synthesis of 7-(1-pyrindanyl)propargyl ethers as rasagiline analogues via chemical or enzymatic resolution of 1-pyrindan-7-ol. RSC Adv. 2015;5:104509

- Ashi Mannan, Thakur Gurjeet Singh, Varinder Singh, Nikhil Garg, Amarjot Kaur, Manjinder Singh. Insights into the Mechanism of the Therapeutic Potential of Herbal
Monoamine Oxidase Inhibitors in Neurological Diseases. CDT 2022;23:286

- Rona R. Ramsay, Giuseppe Di Giovanni. Interdisciplinary Chemical Approaches for Neuropathology. CNS Neurosci Ther 2014;20:571

- Robert Otto, Robert Penzis, Friedemann Gaube, Thomas Winckler, Dorothea Appenroth, Christian Fleck, Christian Tränkle, Jochen Lehmann, Christoph Enzensperger. Beta and gamma carboline derivatives as potential anti-Alzheimer agents: A comparison. European Journal of Medicinal Chemistry 2014;87:63

- Rona Ramsay, Keith Tipton. Assessment of Enzyme Inhibition: A Review with Examples from the Development of Monoamine Oxidase and Cholinesterase Inhibitory Drugs. Molecules 2017;22:1192

- Zhi-Bin Tong, Ruili Huang, Yuhong Wang, Carleen A. Klumpp-Thomas, John C. Braisted, Zina Itkin, Paul Shinn, Menghang Xia, Anton Simeonov, David L. Gerhold. The Toxmatrix: Chemo-Genomic Profiling Identifies Interactions That Reveal Mechanisms of Toxicity. Chem. Res. Toxicol. 2018;31:127

- Viktoriya Ivasiv, Claudia Albertini, Ana E. Gonçalves, Michele Rossi, Maria L. Bolognesi. Molecular Hybridization as a Tool for Designing Multitarget Drug Candidates for Complex Diseases. CTMC 2019;19:1694

- J. Wallach, T. Colestock, A. Adejare. Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders. 2019.

- M. S. Kukharsky, R. K. Ovchinnikov, S. O. Bachurin. Molecular aspects of the pathogenesis and current approaches to pharmacological correction of Alzheimer’s disease. Z. nevrol. psikhiatr. im. S.S. Korsakova 2015;115:103

- Chun-Sing Lam, George Lim Tipoe, Johnny Kong-Ching Wong, Moussa B. H. Youdim, Man-Lung Fung, Kenji Hashimoto. M30 Antagonizes Indoleamine 2,3-Dioxygenase Activation and Neurodegeneration Induced by Corticosterone in the Hippocampus. PLoS ONE 2016;11:e0166966

- Qi Mao, Wang-zhi Qin, Ao Zhang, Na Ye. Recent advances in dopaminergic strategies for the treatment of Parkinson’s disease. Acta Pharmacol Sin 2020;41:471

- Elena V. Mitroshina, Maria V. Vedunova. The Role of Oxygen Homeostasis and the HIF-1 Factor in the Development of Neurodegeneration. IJMS 2024;25:4581
